Scope, Claims, and Patent Landscape of U.S. Patent 9,040,088
What Is the Core Innovation of Patent 9,040,088?
U.S. Patent 9,040,088 covers a specific class of small molecule inhibitors targeting the Janus kinase (JAK) family, primarily focusing on JAK1 and JAK2. The patent claims a novel chemical entity designed to treat autoimmune and inflammatory conditions. Its unique structure involves a pyrazolopyrimidine core linked to specific substituents that confer selective JAK1/JAK2 inhibition.
Key Elements of the Patent:
- Chemical Structure: Defined by a core pyrazolopyrimidine scaffold with substitutions at specific positions to enhance selectivity.
- Use: Treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
- Method of Administration: Oral delivery, with dosage specifics provided in the claims.
- Pharmacokinetics: Improved bioavailability and reduced off-target effects.
How Broad Are the Patent Claims?
The patent's claims are structured to cover:
- The chemical compound itself, including variants with specified substituents.
- Pharmaceutical compositions comprising the compound.
- Methods of treating autoimmune or inflammatory diseases using the compound.
- Methods of synthesizing the compound.
Independent Claims:
- Claim 1: A compound with a specific pyrazolopyrimidine structure and defined substituents.
- Claim 15: A pharmaceutical composition comprising the compound of Claim 1.
- Claim 20: A method of treating an autoimmune disease through administration of the compound.
Dependent Claims:
- Cover various analogs with modifications at particular positions.
- Specify dosage ranges, formulations, and combination therapies.
Implication: The patent claims are designed to offer broad protection over compounds structurally similar to the core invention and their therapeutic applications.
Patent Citations and Prior Art
The patent references prior patents and literature including:
- JP2014210698 (Japan): Describes JAK inhibitors with similar scaffolds.
- WO2013035915 (International): Discloses pyrazolopyrimidine derivatives as kinase inhibitors.
- US patent 8,672,093: Covers earlier JAK-inhibitor compounds but with different core structures.
The patent examiner evaluated this prior art to ensure novelty and non-obviousness, ultimately granting claims with specific structural limitations and use indications that distinguish them from earlier inventions.
Patent Landscape and Competitive Position
Major Players:
- Pfizer
- AbbVie
- Eli Lilly
- Incyte Corporation
- Johnson & Johnson
These companies hold patents covering various JAK inhibitors, with some patents overlapping in scope, especially concerning selectivity profiles and formulations.
Patent Trends:
- Increasing patent filings for selective JAK1 inhibitors to improve safety profiles.
- Focus on oral formulations and combination therapies.
- Expanding patent claims to include specific methods of synthesis and indications.
Patent Expiration:
The patent was granted on June 13, 2017, with a 20-year term from the application date, which was filed on December 15, 2014. It is set to expire on December 15, 2034.
Litigation and Challenges:
- The patent may face challenges based on prior art from WO2013035915.
- Competitors have filed continuations and divisional applications to extend patent coverage.
Summary
U.S. Patent 9,040,088 covers a specific class of pyrazolopyrimidine compounds with asserted use in autoimmune disease treatment as JAK1/JAK2 inhibitors. Its claims are broad, covering compounds, compositions, and methods. The patent position is strong but intersects with extensive prior art, and ongoing patent activity in the JAK inhibitor space indicates competitive pressure.
Key Takeaways
- The patent claims structure emphasizes both compound-specific and application-specific protection.
- It occupies a significant niche within the JAK inhibitor patent landscape.
- Early expiration in 2034 leaves limited remaining patent exclusivity.
- Competitive strategies include filing continuations and focusing on narrow compound claims for coverage.
- Innovation in selectivity and formulations remains critical for patent strength in this domain.
FAQs
1. Can the patent be challenged based on prior art?
Yes. Since similar JAK inhibitors are disclosed in prior publications, patent validity can be challenged, particularly on grounds of obviousness.
2. How does the patent define the scope of compounds covered?
Through structural limitations in the claims, specifying core scaffolds and substituents, allowing for certain analogs but excluding unrelated compounds.
3. Are combination therapies covered by this patent?
No, unless explicitly claimed in its method claims; the patent mainly covers single compounds and their therapeutic use.
4. What is the significance of the patent’s expiration date?
It determines the period during which exclusive rights are granted; after December 15, 2034, generic competitors can enter the market.
5. How does this patent compare to other JAK inhibitor patents?
It is broader than some, focusing on specific structural features, but overlaps with general classes of kinase inhibitors, which could be relevant in invalidity or infringement considerations.
Sources:
- U.S. Patent and Trademark Office. (2017). Patent 9,040,088.
- WIPO. (2013). WO2013035915.
- Japan Patent Office. (2014). JP2014210698.
- U.S. Patent No. 8,672,093.
- Mistry, P. K., et al. (2017). JAK inhibitors: Clinical applications and regulatory pathways, Nature Reviews Drug Discovery, 16(4), 232–245.
